Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar will feature Founder, President and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs, and upcoming milestones. This announcement comes as the company prepares for a pivotal year, with top-line data from its fully enrolled Phase 3 Alzheimer's disease (AD) trial expected in 2027, followed by regulatory submissions.
The webinar will be followed by a live question-and-answer session, providing investors and stakeholders an opportunity to engage directly with the company's leadership. Key topics will include the status of buntanetap, an investigational oral therapy designed to inhibit the translation of multiple neurotoxic proteins implicated in AD and Parkinson's disease (PD). By targeting these underlying causes, Annovis aims to halt disease progression and improve cognitive and motor functions.
In addition to the Phase 3 AD trial, Annovis plans to initiate an open-label study in October 2026 to gather long-term safety data for buntanetap in AD patients. The company also noted that its PD open-label study is already underway, and discussions are ongoing regarding the initiation of a Parkinson's disease dementia program. These initiatives reflect Annovis's strategic expansion across the neurodegenerative disease spectrum, potentially broadening its therapeutic impact.
The announcement holds significant implications for patients and investors alike. For patients, the progression of buntanetap through clinical trials brings hope for a disease-modifying therapy that could alter the trajectory of AD and PD, which currently lack effective treatments. For investors, the upcoming milestones, including the Phase 3 data readout and regulatory submissions, represent critical value inflection points. The success of these trials could position Annovis as a leader in the neurodegenerative space, addressing a vast unmet medical need.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to developing treatments for Alzheimer's and Parkinson's diseases. Its lead candidate, buntanetap (formerly posiphen), is a once-daily oral therapy that works by inhibiting the translation of neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP-43 through a specific RNA-targeting mechanism. This approach aims to address the root causes of neurodegeneration rather than merely managing symptoms.
For more information about the webinar and to access the full press release, visit https://ibn.fm/mls3F. To stay updated on the latest news and developments from Annovis Bio, visit the company's newsroom at https://ibn.fm/ANVS.
